The Zacks Analyst Blog Highlights:U.S. Steel, Carpenter Technology, ArcelorMittal, Companhia Siderurgica Nacional and Novo Nordisk - KMPH FOX 26 | Central San Joaquin Valley News Source

The Zacks Analyst Blog Highlights:U.S. Steel, Carpenter Technology, ArcelorMittal, Companhia Siderurgica Nacional and Novo Nordisk

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE Zacks Investment Research, Inc.

CHICAGO, Feb. 10, 2014 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the U.S. Steel Corporation (NYSE:X-Free Report), Carpenter Technology Corporation (NYSE:CRS-Free Report), ArcelorMittal (NYSE:MT-Free Report), Companhia Siderurgica Nacional (NYSE:SID-Free Report) and Novo Nordisk (NYSE:NVO-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday's Analyst Blog:

U.S. Steel Upgraded to Strong Buy

On Feb 6, Zacks Investment Research upgraded steel company U.S. Steel Corporation (NYSE:X-Free Report) to a Zacks Rank #1 (Strong Buy).

Why the Upgrade?

U.S. Steel, on Jan 27, recorded adjusted earnings of 27 cents per share in the fourth quarter of 2013 against a loss of 41 cents in the year-ago quarter.

For first-quarter 2014, the company expects total reportable segment and other business income from operations to increase moderately compared to the fourth quarter.

U.S. Steel is looking for opportunities related to the availability of reasonably priced natural gas as an alternative to coke in the iron reduction process to improve its cost competitiveness while reducing its dependence on coal and coke in the long term. The company is also expanding its coke-making capabilities. It has taken a number of steps in order to ensure long-term access to high quality coke for its blast furnaces.

U.S. Steel is actively engaged in boosting its position in the energy tubular markets. We note that the shipments of the company's proprietary semi-premium connection increased by nearly 70% in 2013. Moreover, the company continues to introduce new semi-premium and premium connections into the market. These initiatives will enable U.S. Steel to develop connections and capture the significant margin opportunities tied to these highly engineered products.

U.S. Steel expects strong demand in the automotive space. The company had entered into a collaboration agreement with specialty alloy maker Carpenter Technology Corporation (NYSE:CRS-Free Report) to develop lighter high-strength steel for automotive applications in early 2013. The focus of the partnership will be fuel economy and passenger safety.

Moreover, U.S. Steel and Japan's Kobe Steel, in May 2013, commissioned a new continuous annealing line at their joint venture PRO-TEC Coating Company. The 500,000-ton PRO-TEC continuous annealing line will produce the next generation of Advanced High Strength Steels (AHSS) and Ultra High Strength Steels (UHSS) which will possess superior strength, flatness and formability that were earlier not available at these levels.

These better-quality steels offer customers critical design solutions as automotive companies minimize the weight of component materials to improve fuel economy while assuring passenger safety.

The funded status of U.S. Steel's pension and OPEB plans has improved significantly due to the economic recovery. U.S. Steel's total unfunded status at the end of 2013 was $2.5 billion, a $2.4 billion improvement from $4.9 billion at the end of 2012. Pension and OPEB obligations are a significant part of the company's cost and capital structure and U.S. Steel expects its costs to be down over $100 million year over year in 2014.

In addition, U.S. Steel is actively engaged in improving its cost structure and increasing revenues on a sustainable basis through its "Project Carnegie" initiative.

Other Stocks to Consider

Other players in the steel industry worth considering are ArcelorMittal (NYSE:MT-Free Report) and Companhia Siderurgica Nacional (NYSE:SID-Free Report) with both holding a Zacks Rank #1 (Strong Buy).

Update on Novo Nordisk's Diabetes Pipeline

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. Pipelines are of prime importance as far as pharma/biotech companies are concerned. These companies spend a significant amount in advancing their pipelines.

Novo Nordisk's (NYSE:NVO-Free Report) diabetes pipeline includes semaglutide, IDegLira, Tresiba and Ryzodeg. All four candidates are for the treatment of type II diabetes.

Novo Nordisk has a strong presence in the diabetes care market with one of the broadest diabetes portfolios in the industry. Novo Nordisk stated that it commands a 27% market share of the total diabetes care market.

Recently, Novo Nordisk joined forces with Zosano Pharma, Inc. to develop a new transdermal presentation of semaglutide, once weekly GLP-1 analogue. Under this deal, semaglutide will be administered once weekly using Zosano's microneedle patch system for the treatment of type II diabetes.

Firstly, Zosano and Novo Nordisk will carry out preclinical experiments to verify delivery of semaglutide using Zosano's microneedle patch system.

Zosano granted Novo Nordisk an exclusive global license to develop and commercialize semaglutide using Zosano's microneedle patch system. Novo Nordisk will market all products under this deal, subject to approval.

Potential payments to Zosano could total above $60 million for the first product and $55 million for every additional product. Zosano is also eligible to receive royalties on sales of products and will receive development support, as well as reimbursement of all development and manufacturing costs.

We expect the company's diabetes candidates to continue to make progress and contribute to growth.

Novo Nordisk carries a Zacks Rank #4 (Sell).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on X - FREE

Get the full Report on CRS - FREE

Get the full Report on MT - FREE

Get the full Report on SID - FREE

Get the full Report on NVO - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KMPH. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.